JP2022543136A5 - - Google Patents

Info

Publication number
JP2022543136A5
JP2022543136A5 JP2022506919A JP2022506919A JP2022543136A5 JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5 JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022506919 A JP2022506919 A JP 2022506919A JP 2022543136 A5 JP2022543136 A5 JP 2022543136A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
approximately
dose
apoc3
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543136A (ja
JP7829478B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044879 external-priority patent/WO2021026150A1/en
Publication of JP2022543136A publication Critical patent/JP2022543136A/ja
Publication of JP2022543136A5 publication Critical patent/JP2022543136A5/ja
Priority to JP2025012194A priority Critical patent/JP2025061882A/ja
Application granted granted Critical
Publication of JP7829478B2 publication Critical patent/JP7829478B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506919A 2019-08-05 2020-08-04 Ａｐｏｃ３関連疾患および障害の処置のための方法 Active JP7829478B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025012194A JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962883046P 2019-08-05 2019-08-05
US62/883,046 2019-08-05
US201962936559P 2019-11-17 2019-11-17
US62/936,559 2019-11-17
US202062970613P 2020-02-05 2020-02-05
US62/970,613 2020-02-05
PCT/US2020/044879 WO2021026150A1 (en) 2019-08-05 2020-08-04 Methods for the treatment of apoc3-related diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025012194A Division JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Publications (3)

Publication Number Publication Date
JP2022543136A JP2022543136A (ja) 2022-10-07
JP2022543136A5 true JP2022543136A5 (https=) 2023-08-14
JP7829478B2 JP7829478B2 (ja) 2026-03-13

Family

ID=74503223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506919A Active JP7829478B2 (ja) 2019-08-05 2020-08-04 Ａｐｏｃ３関連疾患および障害の処置のための方法
JP2025012194A Pending JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025012194A Pending JP2025061882A (ja) 2019-08-05 2025-01-28 Ａｐｏｃ３関連疾患および障害の処置のための方法

Country Status (9)

Country Link
US (1) US20220152079A1 (https=)
EP (1) EP4010075A4 (https=)
JP (2) JP7829478B2 (https=)
KR (1) KR20220044551A (https=)
CN (1) CN114555188A (https=)
CA (1) CA3147725A1 (https=)
MX (1) MX2022001460A (https=)
TW (1) TW202120104A (https=)
WO (1) WO2021026150A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901841TA (en) * 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
CN114934074A (zh) * 2022-06-01 2022-08-23 北京大学 一种ApoC3基因敲除仓鼠模型的构建方法
AU2024280172A1 (en) 2023-06-01 2025-12-04 Sunshine Lake Pharma Co., Ltd. Novel double-stranded sirna, conjugate thereof, and use thereof
KR20260032888A (ko) * 2024-08-30 2026-03-10 올릭스 주식회사 APOC3 유전자를 표적으로 하는 RNAi 제제 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101383006B1 (ko) * 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
MX390699B (es) * 2011-06-21 2025-03-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
EP2723758B1 (en) * 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
JP2017535552A (ja) * 2014-11-17 2017-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
WO2018112320A1 (en) * 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
CN120330183A (zh) * 2017-06-02 2025-07-18 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
KR20240161202A (ko) * 2017-09-11 2024-11-12 애로우헤드 파마슈티컬스 인코포레이티드 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
EP3719127A4 (en) * 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE

Similar Documents

Publication Publication Date Title
JP2022543136A5 (https=)
JP2015520188A5 (https=)
EA037580B1 (ru) Композиция анти-cgrp антитела
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
JP2022173519A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2023061957A (ja) 抑うつ障害の処置
CN110267648A (zh) 毒蜥外泌肽(9-39)的缓冲制剂
JP6440843B2 (ja) 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
JP2018531605A5 (https=)
JP2025521770A (ja) チルゼパチド組成物及び使用
CN119584980A (zh) 使用mazdutide的治疗方法
JP5837877B2 (ja) 静脈内投与イブプロフェンを用いた患者の治療
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
TW202417015A (zh) 以非妥西蘭治療血友病
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
US20240358668A1 (en) Methods and compisitions for ameliorating biomarkers associated with cardiovascualr risk using (r)-2-amino-3-phenylpropyl carbamate
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
KR20190084334A (ko) 아포지질단백질 제형을 위한 용량 용법
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
KR20230027388A (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
EP3996679A1 (en) High concentration insulin formulation
JP2003171266A (ja) キシリトールを含有する解熱性調剤
Nuffer et al. The Role of inhaled insulin in the management of Type 2 Diabetes